Commit Biologics attending the BioEquity, Milan 2022

April 12 – 2022

Commit Biologics attending the BioEquity, Milan 2022

The BioInnovation Institute supports early-stage life science start-ups that contribute to improving human health for the benefit of people and society. But what are some of the most exciting BII portfolio companies in the biotech space right now? BioInnovation Institute asked their Portfolio Manager, Giles Dudley, and Business Developer, Matthias Wulf. They highlighted six companies including Commit Biologics.

More news

See all news

October 15 – 2024

Commit Biologics appoints Mikkel Wandahl Pedersen as Chief Scientific Officer

Employees Events

Highly experienced leader with demonstrated track record of antibody-based drug discovery and pipeline advancement. Strengthens Commit’s leadership team after emerging from stealth with €16m seed financing. Dr Pedersen will spearhead research and development of …

June 10 – 2024

Commit Biologics to present data on its Bispecific Complement Engaging (BiCE™) platform at the 16th International Conference on Complement Therapeutics

Events News

Commit Biologics is pioneering a novel approach to activating the complement component of the immune system to treat cancer and autoimmune diseases Poster to be presented on Commit’s Bispecific Complement Engaging (BiCE™) platform Aarhus, …

May 9 – 2024

Commit Biologics launches with €16m seed financing to pioneer complement system activation to treat cancer and autoimmune disease

Funding News

Financing led by Bioqube Ventures and Novo Holdings Commit is pioneering a novel approach to activating the complement component of the immune system to treat cancer and autoimmune diseases Its unique bispecific technology (BiCE™) …

For inquiries please contact us
at info@commitbio.com

Commit Biologics ApS
Universitetsbyen 83
8000 Aarhus C, Denmark

+45 3049 7099
LinkedIn